Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01129024 · ClinicalTrials.gov registry record · Phase 2
An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)
A Phase 2 study, sponsored by Shionogi.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01129024 is a Phase 2 study that was terminated before completion, run by Shionogi. The registered enrollment target is 19 participants.
The verdict
NCT01129024, a Phase 2 study, was terminated before completion, sponsored by Shionogi.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The primary objective of this study was to assess the long-term safety of lusutrombopag in the treatment of adults with relapsed persistent or chronic ITP with or without prior splenectomy.
Interventions
- DRUG Lusutrombopag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2010-04-29 |
| Est. Completion | 2011-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01129024
The ClinicalTrials.gov registry entry for NCT01129024 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lusutrombopag is the first listed.
NCT01129024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01129024 about?
NCT01129024 is a clinical study titled "An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)". The primary objective of this study was to assess the long-term safety of lusutrombopag in the treatment of adults with relapsed persistent or chronic ITP with or without prior splenectomy.
What is the current status of trial NCT01129024?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2010-04-29. Estimated completion is 2011-06-30.
What interventions are being tested in trial NCT01129024?
The interventions under investigation include: Lusutrombopag (DRUG).
Who is sponsoring clinical trial NCT01129024?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.